COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase 1 Study of XmAb18968 (CD3-CD38) for the Treatment of Patients With Relapsed/Refractory CD38 Positive Acute Leukemia and T Cell Lymphoblastic Lymphoma

Protocol No
IIT-ATALLAH-MCW-XEN21
Principal Investigator
Ehab Atallah
Phase
I
Summary
Determine the toxicity profile of XmAb18968 in subjects with relapsed/refractory acute leukemia/T-LBL.
Description
To determine the recommended Phase 2 dose (RP2D) and tolerability profile of XmAb18968 in subjects with relapsed/refractory acute leukemia and T-LBL with CD38 expression
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL